Liquid Biopsy Market by Biomarkers (Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Sample (Blood Based, Urine Based), Type, Technology, Indication, End-User, Application - Global Forecast 2024-2030

Liquid Biopsy Market by Biomarkers (Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA), Sample (Blood Based, Urine Based), Type, Technology, Indication, End-User, Application - Global Forecast 2024-2030

The Liquid Biopsy Market size was estimated at USD 1.70 billion in 2023 and expected to reach USD 2.05 billion in 2024, at a CAGR 20.39% to reach USD 6.25 billion by 2030.

Global Liquid Biopsy Market Liquid biopsy has emerged as an effective and non-invasive alternative to surgical biopsies, allowing medical professionals to provide accurate information about a tumor through a blood sample. They have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. The world observes an increase in the number of cancer patients with a huge preference for non-invasive diagnostics procedures, including liquid biopsies. The exponential potential of liquid biopsies in cancer detection has led to more research activities being conducted to amplify their usage. However, limited reimbursement offerings for the procedure and stringent regulations regarding their accuracy and usage significantly limit product adoption across hospitals. Product developers are developing a cost-effective line of liquid biopsies and introducing microarrays and next-generation sequencing technologies in these biopsies to improve their operational characteristics. The technology of liquid biopsies is still evolving, and its non-invasive nature promises to open new eras in clinical oncology.Regional InsightsThe liquid biopsy market in the Americas and Europe is highly organized, with prominent market players developing advanced liquid biopsy diagnostics and substantial government assistance for cancer research. Several players have also received United States patents for their liquid biopsy technologies, creating an opportunity for growth in this medical approach. The Asia-Pacific nations, including Thailand, Malaysia, the Philippines, Australia, Indonesia, and Singapore, are expanding their healthcare sectors with significant investments to create a strengthened service associated with early cancer diagnostics. In May 2022, the Australian Cancer Research Foundation (ACRF) Child Cancer Liquid Biopsy Program launched a liquid biopsy program in Sydney, representing the cancer sampling and monitoring revolution. Governments in Asia have approved liquid biopsies considering the need to improve cancer diagnosis. In context, the China Food and Drug Administration (CFDA) approved Amoy Diagnostics' EGFR mutation liquid biopsy for use in 2018. Moreover, concerns regarding the prevalence of cancer, growing research initiatives, and the rapidly developing healthcare sector are expected to expand the need for liquid biopsy across the Middle East & Africa.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liquid Biopsy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liquid Biopsy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, Biocept, Inc., CellMax, Inc., Circulogene, Diacarta, Dxcover Limited, Epic Sciences, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Guardant Health, Inc., Illumina Inc., Inivata Limited by NeoGenomics, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems Inc., Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., OncoDNA, PerkinElmer, Inc., Personalis, Inc., SAGA Diagnostics AB, Strand Life Sciences Pvt. Ltd., Sysmex Corporation, and Tempus.

Market Segmentation & Coverage

This research report categorizes the Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Biomarkers
Cell-free DNA

Circulating Tumor Cells

Circulating Tumor DNA

Exosome

Extracellular Vesicles

Sample
Blood Based

Urine Based

Type
Assay Kits

Instruments

Services

Technology
Multi-gene Parallel Analysis using NGS

Single-gene Analysis using PCR Microarrays

Indication
Cancer Indication
Breast Cancer

Colorectal Cancer

Lung Cancer

Melanoma

Prostate Cancer

Non-Cancer Indication

End-User
Academic & Research Centers

Clinical Diagnostic Laboratories

Hospitals

Physician’s Office Laboratories

Application
Early Cancer Screening

Recurrence Monitoring

Therapy Selection

Treatment Monitoring

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Liquid Biopsy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liquid Biopsy Market?
3. What are the technology trends and regulatory frameworks in the Liquid Biopsy Market?
4. What is the market share of the leading vendors in the Liquid Biopsy Market?
5. Which modes and strategic moves are suitable for entering the Liquid Biopsy Market?

Note: PDF & Excel + Online Access - 1 Year